Lantern Pharma (LTRN) EBT (2020 - 2026)

Lantern Pharma (LTRN) has reported EBT for 7 consecutive years, with -$3.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 23.34% year-over-year to -$3.5 million; the trailing twelve-month figure through Jun 2026 stood at -$15.2 million (up 23.46% YoY), and the FY2025 full-year result was -$17.5 million, up 18.32% from the prior year.
• EBT declined to -$3.5 million in Q2 2026 per LTRN's latest filing, from -$3.4 million in the prior quarter.
• Across five years, EBT topped out at -$2.3 million in Q3 2022 and bottomed at -$5.7 million in Q4 2024.
• Historically, EBT has averaged -$4.3 million across 5 years, with a median of -$4.4 million in 2022.
• The widest YoY moves for EBT: up 44.4% in 2022, down 83.39% in 2022.
• Over 5 years, EBT stood at -$3.7 million in 2022, then slipped by 23.66% to -$4.6 million in 2023, then decreased by 24.4% to -$5.7 million in 2024, then increased by 27.98% to -$4.1 million in 2025, then advanced by 15.79% to -$3.5 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$3.5 million, -$3.4 million, and -$4.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.